Abstract
1
The American Cancer Society has projected 224,390 Americans will receive a new diagnosis of lung cancer in 2016. This represents a dramatic increase in both incidence and prevalence of the disease, as the United States had approximately 157,426 deaths attributable to lung cancer in 2012. 2 While the incidence of lung cancer has increased across all demographics, male mortality from lung cancer actually saw a reduction between 1990 and 2007 while women saw an increase of 6.31% in mortality over that same time span. 1, 2 This is likely attributable to the early peak of smoking rates in men compared to women.
Increasing pack-years, African-American race, low income, lesser education, and occupational exposures are all associated with increased lung cancer rates as well.
History and Information about Statins
In 1971, Dr. Akira Endo set out to develop a medication that would theoretically decrease coronary artery disease by decreasing cholesterol production. By 1992, >1 million people had been prescribed a statin class medication. 
RAS
The RAS family plays a key role in oncogenesis. in vitro studies to overcome the gefitinib resistance of the KRAS mutation in NSCLC 29, 30 . .
Family members include HRAS, KRAS, and NRAS. RAS

Radiation Therapy
The use of radiotherapy is a useful adjunct for In a phase 2 study, patients with NSCLC were randomized to receive gefitinib plus simvastatin (52 patients) versus gefitinib alone (54 patients) 49 .
Primary endpoints were response rate, and secondary end points were toxicity, progression-free survival (PFS), and overall survival (OS . Receptor resistance to tyrosine kinase inhibitors has been described as 'inevitable' and remains a constant frustration. Atorvastatin has been demonstrated in multiple in vitro studies to overcome the gefitinib resistance of the KRAS mutation in NSCLC 29, 30 .
Platinum-based chemotherapy is commonly used in the various types of chemotherapy regimens for treatment of lung cancer. Similar to tyrosine kinase inhibitors, resistance developed from malignant cells against platinum-agents is an all to common occurrence.
In NSCLC, atorvastatin was found to antagonize platinum-resistance and enhance the efficiency of apoptosis induced by carboplatin 36 . Funding: There was no funding for this study.
